Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Alpine Immune Sciences (ALPN)

Alpine Immune Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALPN
DateTimeSourceHeadlineSymbolCompany
11/04/202421:27PR Newswire (US)Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law FirmNASDAQ:ALPNAlpine Immune Sciences Inc
11/04/202412:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:ALPNAlpine Immune Sciences Inc
10/04/202421:15Business WireAlpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA NephropathyNASDAQ:ALPNAlpine Immune Sciences Inc
10/04/202421:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences Inc
10/04/202421:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences Inc
01/04/202414:00Business WireAlpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024NASDAQ:ALPNAlpine Immune Sciences Inc
21/03/202411:45Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024NASDAQ:ALPNAlpine Immune Sciences Inc
20/03/202420:30Business WireAlpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
18/03/202420:05Business WireAlpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
07/03/202421:30Business WireAlpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
26/02/202421:30Business WireAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesNASDAQ:ALPNAlpine Immune Sciences Inc
14/02/202421:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
14/02/202414:22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
07/02/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
01/02/202421:30Business WireAlpine Immune Sciences to Participate in Two Upcoming Healthcare ConferencesNASDAQ:ALPNAlpine Immune Sciences Inc
22/01/202423:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
05/01/202423:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
05/01/202423:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
05/01/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
05/01/202400:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
05/01/202400:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALPNAlpine Immune Sciences Inc
21/12/202321:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALPNAlpine Immune Sciences Inc
21/12/202321:15Business WireAlpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVieNASDAQ:ALPNAlpine Immune Sciences Inc
18/12/202321:30Business WireAlpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
22/11/202315:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALPNAlpine Immune Sciences Inc
20/11/202321:30Business WireAlpine Immune Sciences to Participate in the Evercore ISI HealthconX ConferenceNASDAQ:ALPNAlpine Immune Sciences Inc
15/11/202314:00Business WireAlpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
14/11/202321:15Business WireAlpine Immune Sciences Reports Third Quarter 2023 Financial ResultsNASDAQ:ALPNAlpine Immune Sciences Inc
13/11/202314:00Business WireAlpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023NASDAQ:ALPNAlpine Immune Sciences Inc
07/11/202302:41Business WireAlpine Immune Sciences Announces Pricing of $150 Million Public OfferingNASDAQ:ALPNAlpine Immune Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:ALPN